Company type | Public |
---|---|
TYO: 4506 | |
Industry | |
Predecessors |
|
Founded | October 1, 2005 | (merger of Dainippon Pharmaceuticals & Sumitomo Pharmaceuticals)
Headquarters | Doshomachi, Chuo-ku, Osaka, Japan |
Key people | Hiroshi Nomura, (president and CEO) |
Brands | |
Revenue | $4.18 billion (¥555.54 billion) (FY 2022)[* 1] |
-$580 million (-¥77.0 billion) (FY 2022)[* 1] | |
-$728 million (-¥96.7 billion) (FY 2022)[* 1] | |
Total assets | $8.55 billion (¥1,134.7 billion) (FY 2022)[* 1] |
Total equity | $3.06 billion (¥406.8 billion) (FY 2022)[* 1] |
Number of employees | 6,250 (consolidated) 3,026 (non-consolidated) (as of March 31, 2023) |
Website | www |
Footnotes / references |
Sumitomo Pharma Company Limited (住友ファーマ株式会社, Sumitomo Fāma Kabushiki-Gaisha) is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka.[1]